The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial ...

Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...

INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ — Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, ...

The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnc ...

US-based Normunity has raised $75m in a Series B funding round to support the clinical development of its lead programme, NRM-823, a potential first-in-class T-cell engager (TCE) targeting solid ...

Request To Download Free Sample of This Strategic Report @ Catalysts of Market Growth: The buoyant growth trajectory of the global monoclonal antibodies market is propelled by a convergence of ...

UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...